We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Assessment of Potential Interactions Between GBR 12909 and Cocaine - 1

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified March 2005 by National Institute on Drug Abuse (NIDA).
Recruitment status was:  Active, not recruiting
ClinicalTrials.gov Identifier:
First Posted: December 23, 2004
Last Update Posted: January 11, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
National Institute on Drug Abuse (NIDA)
December 22, 2004
December 23, 2004
January 11, 2017
June 2004
Not Provided
Heart rate
Same as current
Complete list of historical versions of study NCT00100113 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Assessment of Potential Interactions Between GBR 12909 and Cocaine - 1
Study of Interactions Between GBR 12909 and Cocaine
The purpose of this study is to assess potential interactions between intravenous (IV) cocaine and 3 doses of GBR 12909.
This is Phase 1, double-blind, placebo-controlled human laboratory clinical pharmacology study that will assess the potential interactions between IV cocaine and 3 escalating oral doses of GBR 12909. The primary objective is to determine safety of GBR 12909 administration and if there are significant interactions between GBR 12909 treatment concurrent with IV cocaine infusions.
Phase 1
Primary Purpose: Treatment
Cocaine-Related Disorders
Drug: GBR 12909
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Unknown status
June 2005
Not Provided

Inclusion Criteria:

  • Must be within 20% ideal body weight and must weigh at least 45 kg.
  • Must understand the study procedures and provide written informed consent.
  • Must meet DSM-4 criteria and are non-treatment seeking at time of study.

Exclusion Criteria:

  • Please contact study site for more information
Sexes Eligible for Study: All
18 Years to 45 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Not Provided
Not Provided
National Institute on Drug Abuse (NIDA)
Not Provided
Principal Investigator: Kathryn Cunningham, Ph.D. University of Texas Medical Branch - Galveston
National Institute on Drug Abuse (NIDA)
March 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP